| P2093 | author name string | Yosef Yarden | |
| | Bilha Schechter | |
| | Michael Sela | |
| | Ruth Maron | |
| | Georg Mahlknecht | |
| | Maicol Mancini | |
| P2860 | cites work | Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 |
| | A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies | Q27675148 |
| | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 |
| | Cancer statistics, 2010 | Q27860525 |
| | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 |
| | Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes | Q28307762 |
| | Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function | Q28678683 |
| | EGF-ERBB signalling: towards the systems level | Q29619032 |
| | Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 |
| | An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation | Q33733313 |
| | Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy | Q33837881 |
| | Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers | Q33888963 |
| | Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. | Q34067821 |
| | Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice | Q34169387 |
| | Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials | Q34428750 |
| | In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption | Q35836035 |
| | Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells | Q36098160 |
| | Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. | Q36583011 |
| | EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma | Q36696146 |
| | Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis | Q37117664 |
| | Systems biology of growth factor-induced receptor endocytosis | Q37381801 |
| | Cancer therapeutic antibodies come of age: targeting minimal residual disease | Q37453793 |
| | A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines | Q39428554 |
| | Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. | Q39752760 |
| | Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 |
| | In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas | Q40124759 |
| | A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies | Q40552147 |
| | Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. | Q40725921 |
| | Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. | Q40866492 |
| | ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 |
| | Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation | Q41710300 |
| | Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies | Q42819445 |
| | Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo | Q43683948 |
| | Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. | Q54649058 |
| | A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors | Q73359246 |
| | Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization | Q84191383 |
| P433 | issue | 38 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| | pancreatic carcinoma | Q18556536 |
| P304 | page(s) | 15389-15394 | |
| P577 | publication date | 2013-09-03 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 | |
| P478 | volume | 110 | |